Wormaway Plus XL Tablets For Dogs

国: アイルランド

言語: 英語

ソース: HPRA (Health Products Regulatory Authority)

有効成分:

Praziquantel; Pyrantel embonate ; Febantel

から入手可能:

Chanelle Pharmaceuticals Manufacturing Limited

ATCコード:

QP52AA01; QP52AC05; QP52AF02

INN（国際名）:

Praziquantel; Pyrantel embonate ; Febantel

投薬量:

175,504,525 mg/tablet

医薬品形態:

Tablet

処方タイプ:

CAM: Companion Animal Medicine as defined in relevant national legislation

治療群:

Dogs

治療領域:

praziquantel; febantel; pyrantel

適応症:

Endoparasiticide

認証ステータス:

Authorised

承認日:

2013-04-12

製品の特徴

1
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Wormaway Plus XL Tablets For Dogs
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each tablet contains:
ACTIVE SUBSTANCES:
Praziquantel
175 mg
Pyrantel Embonate
504 mg (equivalent to 175 mg pyrantel)
Febantel
525 mg
EXCIPIENTS:
QUALITATIVE
COMPOSITION OF EXCIPIENTS AND OTHER CONSTITUENTS
Lactose monohydrate
Microcrystalline cellulose
Magnesium stearate
Colloidal anhydrous silica
Croscarmellose sodium
Sodium lauryl sulfate
Pork flavour
A yellow coloured oblong tablet with a breakline on both sides.
The tablets can be divided into two equal parts.
3.
CLINICAL INFORMATION
3.1
TARGET SPECIES
Dogs.
3.2
INDICATIONS FOR USE FOR EACH TARGET SPECIES
Treatment of mixed infections by nematodes and cestodes of the
following species
NEMATODES:
ASCARIDS:
_Toxocara canis_
,
_Toxascaris leonina_
(adult and late immature forms).
HOOKWORMS:
_Uncinaria stenocephala_
,
_Ancylostoma caninum_
(adults).
WHIPWORMS:
_Trichuris vulpis_
(adults).
CESTODES:
TAPEWORMS:
_Echinococcus_
species
_(E. granulosus, E. multilocularis), Taenia_
species
_(T. hydatigena, T. pisiformis, T. taeniformis), Dipylidium caninum_
(adult and immature forms).
3.3
CONTRAINDICATIONS
2
Do not use in cases of hypersensitivity to the active substances or to
any of the excipients.
Do not use during the 1st and 2nd trimester of pregnancy (see section
3.7)
3.4
SPECIAL WARNINGS
Fleas serve as intermediate hosts for one common type of tapeworm –
_Dipylidium caninum_
.
Tapeworm infestation is certain to reoccur unless control of
intermediate hosts such as fleas,
mice, etc. is undertaken.
Parasite resistance to any particular class of anthelmintic may
develop following frequent,
repeated use of an anthelmintic of that class.
To minimise the risk of reinfestation and new infestation, excreta
should be collected and
properly disposed of for 24 hours following treatment.
3.5
SPECIAL PRECAUTIONS FOR USE
Special precautions for safe use in the target species:
Not Applicable.
Special precautions to be taken by the person administering t